• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MYR
Click for more information
0.00% 82.5¢

MYER HOLDINGS LIMITED - Charts / Financials

Market Cap $693.0M  ! watchlist Created with Sketch. Add to my watchlist

Myer Holdings Limited is an Australia-based company that is engaged in the department... Myer Holdings Limited is an Australia-based company that is engaged in the department store business. The Company operates approximately 56 department stores across Australia, as well as its online business, myer.com.au. The Company’s merchandise offer includes core product categories: Womenswear; Menswear; Childrenswear; Beauty; Homewares; Electrical Goods; Toys and General Merchandise. The Company's operations are in Australia and encompass Myer department stores, sass & bide, and Marcs and David Lawrence (MDL). It directly sources products from over 250 suppliers across 12 countries for its private-label brands. It offers a loyalty program, MYER one, where members earn credits on purchases at Myer that convert into reward cards on a quarterly basis. Its subsidiaries include NB Elizabeth Pty Ltd, NB Russell Pty Ltd, NB Lonsdale Pty Ltd, NB Collins Pty Ltd, Warehouse Solutions Pty Ltd, Myer Group Pty Ltd, Myer Pty Ltd, Myer Group Finance Limited and The Myer Emporium Pty Ltd.More

refresh Created with Sketch. REFRESH
Last update - 11.36am 02/10/2024 (20 minute delay) ?
Day
Open 83.0¢   Day High 83.0¢   Day Low 82.5¢
Daily Volume 241875
Bids   Sellers
Number Price Volume   Number Price Volume
5 82.5¢ 13844   9 83.0¢ 100640

Directors & Senior Management

Ms. Olivia Wirth Executive Chairman of the Board, Chief Executive Officer
Mr. Matt Jackman Chief Financial Officer
Mr. Anthony Sutton Chief Operating Officer
Mr. Paul Morris General Counsel, Company Secretary
Mr. Allan Winstanley Chief Merchandise Officer
Dr. Gary Weiss Deputy Chairman of the Board, Non-Executive Lead Independent Director
Mr. Terrence Mccartney Non-Executive Director
Mr. Robert Perry Non-Executive Director
Ms. Jacqueline Elizabeth Naylor Non-Executive Independent Director
Mr. David Charles Hunter Whittle Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
82.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $693.0M
Open High Low Value Volume
83.0¢ 83.0¢ 82.5¢ $200.3K 241.8K

Buyers (Bids)

No. Vol. Price($)
5 13844 82.5¢
 

Sellers (Offers)

Price($) Vol. No.
83.0¢ 100640 9
View Market Depth
Last trade - 11.16am 02/10/2024 (20 minute delay) ?
Last
82.5¢ 		  Change
0.000 ( 0.30 %)
Open High Low Volume
82.5¢ 83.0¢ 82.5¢ 25677
Last updated 11.36am 02/10/2024 ?

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t Maximus Resources (ASX:MXR) has unveiled its latest drilling assay results at Eagles Nest, hitting gold downhole multiple assets.
PainChek close to finding out if FDA approves its flagship app for use in dementia care PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.